COMMUNIQUÉS West-GlobeNewswire

Stereotaxis Reports 2024 Third Quarter Financial Results
11/11/2024
ST. LOUIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the third [...]
Assertio Reports Third Quarter 2024 Financial Results
11/11/2024
Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings [...]
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
11/11/2024
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, [...]
Celldex Therapeutics to Present at Upcoming Investor Conferences
11/11/2024
HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: Guggenheim Healthcare Innovation [...]
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
11/11/2024
NEWTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers [...]
Norton West Louisville Hospital opens
11/11/2024
$90 million facility aims to improve access to care for residents in historically underserved area of the city LOUISVILLE, Ky., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Norton West Louisville Hospital opened its doors to [...]
UPDATE - New Paper: Leading Health Economists Explain How to Fix the Faulty & Outdated Models Used to Calculate the Value of Medicines
11/11/2024
Access to Life-Saving Drugs can be Delayed or Denied when Regulators and Health Plans Rely on Outdated Cost-Effectiveness Analysis (CEA) Methodology WASHINGTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- As policymakers [...]
French Biotech Company AdipoPharma Secures Funding to Initiate Clinical Trials for its first-in-class compound for Insulin Resistance
11/11/2024
Global Investments Pave Way for Breakthrough Treatment for Type 2 Diabetes STRASBOURG, France, Nov. 11, 2024 (GLOBE NEWSWIRE) -- AdipoPharma , a biotech company headquartered in France with offices in the US and Belgium [...]
Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions
11/11/2024
Allschwil, Switzerland – November 11, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data on aprocitentan, the first-and-only dual endothelin receptor antagonist (ERA) for the treatment of systemic hypertension, [...]
QC Kinetix National Medical Director Dr. Mitchell Sheinkop is the Keynote Speaker at the International Conference on Stem Cells and Regenerative Medicine
11/11/2024
Dr. Sheinkop will advise physicians involved in Regenerative Medicine worldwide on “Translating the Potential of OrthoBiologics Treatment into Clinical Practice” Dr. Mitchell Sheinkop CHARLOTTE, N.C., Nov. 11, 2024 ( [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
11/11/2024
Company announcement – No. 50 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, [...]
PETVIVO HOLDINGS, INC. TO ANNOUNCE RESULTS FOR THE SECOND QUARTER ENDED SEPTEMBER 30, 2024
11/11/2024
MINNEAPOLIS, MN, US, Nov. 11, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV and PETVW), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for [...]
New Paper: Leading Health Economists Explain How to Fix the Faulty & Outdated Models Used to Calculate the Value of Medicines
11/11/2024
Access to Life-Saving Drugs can be Delayed or Denied when Regulators and Health Plans Rely on Outdated Cost-Effectiveness Analysis (CEA) Methodology WASHINGTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- As policymakers [...]
ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024
11/11/2024
GARDEN CITY, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that they will be [...]
Johnson & Johnson dépose des demandes d’autorisation aux États-Unis et dans l’Union européenne du DARZALEX FASPRO®/DARZALEX® (daratumumab) en tant que monothérapie sous-cutanée destinée au traitement du myélome multiple indolent à haut risq
11/11/2024
En cas d’obtention de l’autorisation, le daratumumab deviendra la première option thérapeutique pour les patients atteints d’un myélome multiple indolent et présentant un risque élevé de développer un myélome multiple, [...]
AMN Healthcare Commits to Science-Based Targets, Leading the Charge Towards a Sustainable Future
11/11/2024
DALLAS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- AMN Healthcare, the leader and innovator in total talent solutions for healthcare organizations, announces it has approved near and long-term science-based emissions reduction [...]
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
11/11/2024
MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related [...]
NEXGEL to Report Third Quarter 2024 Financial Results on November 13th
11/11/2024
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, [...]
Cerevance’s CVN293 Demonstrated Positive Phase 1 Results in Healthy Volunteers
11/11/2024
CVN293 was generally well-tolerated in healthy volunteers for up to 14-days of continuous dosing Dose-dependent exposure was observed with evidence of robust brain penetration Data supports potential advancement into [...]

Pages